Abbott Labs Buys Rights to PanGenetics Drug
Abbott Labs has agreed to acquire the global rights to an antibody to nerve growth factor from PanGenetics BV, a Dutch antibody developer. The deal includes a $170 million up-front payment and up to $20 million in additional earn-outs. PanGenetics has raised VC funding from Edmond de Rothschild Investment Partners, Biogen Idec New Ventures, Fortis Private Equity, Index Ventures, Forbion Capital Partners and Credit Agricole Private Equity.
12 November 2009•2 mins read
